BioLineRx Ltd.
BLRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$2.03
KIRA · Stoqly’s AI analyst, in plain words
- BioLineRx Ltd. had $1.2M of revenue in fiscal 2025, down 95.9% on the year before.
- Its operating margin was −871.8%, down 801.3 pts: of every 100 in sales, about −872 is left after running the business.
- BioLineRx Ltd. lost $2.0M in fiscal 2025.
- Free cash flow was −$8.1M in fiscal 2025, −686.4% of revenue.
Market cap
—
P/E
—
Revenue
$1.2M
Net income
−$2.0M
Free cash flow
−$8.1M
Operating margin
−871.8%
BioLineRx Ltd. in 30 seconds · fiscal 2025
Are sales growing?
−95.9%
No. Sales fell 95.9% last year.
Does it make a profit?
−171.7%
No. It lost money last year.
Does profit turn into cash?
−686.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
What BioLineRx Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 23, 2026
- Legal name
- BioLineRx Ltd.
- CIK
- 0001498403
BioLineRx Ltd. · BLRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $4.8M | $28.9M | $1.2M |
| Revenue growth | — | — | — | 502.9% | −95.9% |
| Gross margin | — | — | 23.1% | 68.0% | 80.5% |
| Operating margin | — | — | −1,035.3% | −70.5% | −871.8% |
| Net income | −$27.1M | −$25.0M | −$60.6M | −$9.2M | −$2.0M |
| Net margin | — | — | −1,262.8% | −31.9% | −171.7% |
| Diluted EPS | −$0.04 | −$0.03 | −$0.06 | −$0.01 | $0.00 |
| Cash | |||||
| Cash from operations | −$23.6M | −$26.2M | −$22.6M | −$43.9M | −$8.1M |
| Capital expenditure | $0.1M | $0.1M | $0.1M | $0.1M | $0.0M |
| Free cash flow | −$23.7M | −$26.4M | −$22.7M | −$43.9M | −$8.1M |
| FCF margin | — | — | −473.4% | −151.8% | −686.4% |
| Share count change | 162.2% | 16.7% | 24.5% | 24.4% | 105.8% |
| Debt and strength | |||||
| Cash and short-term investments | $13.0M | $10.6M | $4.3M | $10.4M | $3.3M |
| Shareholders' equity | $68.1M | $50.8M | $13.2M | $13.5M | $18.2M |
| Current ratio | 5.9x | 4.9x | 1.1x | 1.8x | 2.0x |
| Interest coverage | −25.2x | −16.3x | −23.2x | −2.2x | −8.2x |
| Returns and quality | |||||
| Return on equity | −60.0% | −42.0% | −189.2% | −69.1% | −12.8% |
| Return on tangible equity | −58.3% | −86.2% | — | −306.1% | −110.8% |
| Piotroski F-score | — | 1 | 2 | 4 | 3 |
| Altman Z'' | −5.0 | −11.0 | −24.4 | −34.5 | −30.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
BioLineRx Ltd. · BLRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.03 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001498403). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.